Exact Mass: 309.19667799999996
Exact Mass Matches: 309.19667799999996
Found 104 metabolites which its exact mass value is equals to given mass value 309.19667799999996,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Metipranolol
Metipranolol is only found in individuals that have used or taken this drug. It is a beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent. [PubChem]Although it is known that metipranolol binds the beta1 and beta2 adrenergic receptors, the mechanism of metipranolols action is not known. It has no significant intrinsic sympathomimetic activity, and has only weak local anesthetic (membrane-stabilizing) and myocardial depressant activity. It appears that the ophthalmic beta-adrenergic blocking agents reduce aqueous humor production, as demonstrated by tonography and fluorophotometry. A slight increase in aqueous humor outflow may be an additional mechanism. S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics > S01ED - Beta blocking agents C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents Metipranolol is a nonselective and orally active β-adrenergic receptor antagonist. Metipranolol can be used for hypertension and glaucoma research[1][2].
Nadolol
C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AA - Beta blocking agents, non-selective C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents CONFIDENCE standard compound; EAWAG_UCHEM_ID 3072 Nadolol (SQ-11725) is a non-selective and orally active β-adrenergic receptors blocker and is a substrate of organic anion transporting polypeptide 1A2 (OATP1A2). Nadolol has the the potential for high blood pressure, angina pectoris and vascular headaches research[1][2][3].
Nadolol
Nadolol is only found in individuals that have used or taken this drug. It is a non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for migraine disorders and for tremor. [PubChem]Like other beta-adrenergic antagonists, nadolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, nadolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure. It also blocks beta-2 adrenergic receptors located in bronchiole smooth muscle, causing vasoconstriction. By binding beta-2 receptors in the juxtaglomerular apparatus, nadolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production. Nadolol therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively. C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AA - Beta blocking agents, non-selective C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents Nadolol (SQ-11725) is a non-selective and orally active β-adrenergic receptors blocker and is a substrate of organic anion transporting polypeptide 1A2 (OATP1A2). Nadolol has the the potential for high blood pressure, angina pectoris and vascular headaches research[1][2][3].
(2E,5Z,7E)-Decatrienoylcarnitine
(2E,5Z,7E)-Decatrienoylcarnitine is an acylcarnitine. More specifically, it is an (2E,5Z,7E)-decatrienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E,5Z,7E)-Decatrienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2E,5Z,7E)-Decatrienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(2Z,4E,6Z)-Decatrienoylcarnitine
(2Z,4E,6Z)-Decatrienoylcarnitine is an acylcarnitine. More specifically, it is an (2Z,4E,6Z)-deca-2,4,6-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2Z,4E,6Z)-Decatrienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2Z,4E,6Z)-Decatrienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(3Z,5E,7E)-Decatrienoylcarnitine
(3Z,5E,7E)-Decatrienoylcarnitine is an acylcarnitine. More specifically, it is an (3Z,5E,7E)-deca-3,5,7-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (3Z,5E,7E)-Decatrienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (3Z,5E,7E)-Decatrienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(2E,6E,8E)-Decatrienoylcarnitine
(2E,6E,8E)-Decatrienoylcarnitine is an acylcarnitine. More specifically, it is an (2E,6E,8E)-deca-2,6,8-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E,6E,8E)-Decatrienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2E,6E,8E)-Decatrienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(2E,4E,7E)-Decatrienoylcarnitine
(2E,4E,7E)-Decatrienoylcarnitine is an acylcarnitine. More specifically, it is an (2E,4E,7E)-deca-2,4,7-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E,4E,7E)-Decatrienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2E,4E,7E)-Decatrienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Solgol
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents Nadolol (SQ-11725) is a non-selective and orally active β-adrenergic receptors blocker and is a substrate of organic anion transporting polypeptide 1A2 (OATP1A2). Nadolol has the the potential for high blood pressure, angina pectoris and vascular headaches research[1][2][3].
(9Z,11E,14Z)-(13S)-hydroperoxyoctadeca-(9,11,14)-trienoate
(9z,11e,14z)-(13s)-hydroperoxyoctadeca-(9,11,14)-trienoate is practically insoluble (in water) and a weakly acidic compound (based on its pKa). (9z,11e,14z)-(13s)-hydroperoxyoctadeca-(9,11,14)-trienoate can be found in a number of food items such as wasabi, european chestnut, savoy cabbage, and prunus (cherry, plum), which makes (9z,11e,14z)-(13s)-hydroperoxyoctadeca-(9,11,14)-trienoate a potential biomarker for the consumption of these food products.
Macusine B
[C20H25N2O]+ (309.19667799999996)
Origin: Plant; SubCategory_DNP: Monoterpenoid indole alkaloids, Bisindole alkaloids, Indole alkaloids
CAR 10:3
2-ethylhexyl prop-2-enoate,prop-2-enenitrile,prop-2-enoic acid
N,N-DIMETHYL-N-[3-(SULFOOXY)PROPYL]-1-NONANAMINIUM HYDROXIDE, INNER SALT
6-methylheptyl prop-2-enoate,prop-2-enenitrile,prop-2-enoic acid
bis(2-hydroxyethyl)-3-aminopropyltriethoxysilane
C13H31NO5Si (309.19713959999996)
3-pyridin-3-yl-6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyridazine
3-pyridin-4-yl-6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyridazine
[4-[2-(4-cyclopropylpiperazin-1-yl)pyrimidin-5-yl]phenyl]methanamine
3-((Phenylamino)methyl)phenylboronic acid, pinacol ester
1-Tert-butyl-3-(2,5-dimethylbenzyl)-1H-pyrazolo[3,4-D]pyrimidin-4-amine
2,3-Naphthalenediol, 5-((2R)-3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-, (2S,3R)-rel-
2,3-Naphthalenediol, 5-((2R)-3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-, (2R,3S)-rel-
(19E)-4-methylsarpagan-4-ium-17-ol
C20H25N2O+ (309.19667799999996)
(1S,4R,7AR)-4-Butoxy-1-[(1R)-1-formylpropyl]-2,4,5,6,7,7A-hexahydro-1H-isoindole-3-carboxylic acid
(9Z,11E,13S,15Z)-13-Hydroperoxyoctadeca-9,11,15-trienoate
Conjugate base of (9Z,11E,13S,15Z)-13-hydroperoxyoctadeca-9,11,15-trienoic acid.
(9S,10E,12Z,15Z)-9-hydroperoxyoctadeca-10,12,15-trienoate
(9R,10E,12Z,15Z)-9-hydroperoxyoctadeca-10,12,15-trienoate
(8E,10S,12Z,15Z)-10-hydroperoxyoctadec-8,12,15-trienoate
(2S)-3-methyl-2-[[2-[(1R,2R)-3-oxo-2-[(Z)-pent-2-enyl]cyclopentyl]acetyl]amino]butanoic acid
(9Z,11E,13S,14Z)-13-hydroperoxyoctadeca-9,11,14-trienoate
The conjugate base of (9Z,11E,13S,14Z)-13-hydroperoxyoctadeca-9,11,14-trienic acid.
(2S)-2-[[2-[(2Z)-2-Pentenyl]-3-oxocyclopentyl]acetylamino]-3-methylbutyric acid
(9E,11E,14E)-13-hydroperoxyoctadeca-9,11,14-trienoate
(R)-2-hydroperoxy-alpha-linolenate
A hydroperoxy fatty acid anion that is the conjugate base of (R)-2-hydroperoxy-alpha-linolenic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(10E,12Z,15Z)-9-hydroperoxyoctadeca-10,12,15-trienoate
10-HPO(6,8,12)TrE(1-)
A polyunsaturated fatty acid anion that is the conjugate base of 10-HPO(6,8,12)TrE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
10(R)-HPO(6,8,12)TrE(1-)
A polyunsaturated fatty acid anion that is the conjugate base of 10(R)-HPO(6,8,12)TrE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
12,13-epoxy-(10R)-hydroxy-(8E,15Z)-octadecadienoate
2-Trimethylsilyloxy-N-(2-(diethylamino)ethyl)-3-pyridinecarboxamide
C15H27N3O2Si (309.18724419999995)
4-(3-(4-(3-Hydroxybutoxy)phenoxy)propyl)morpholine
2-(3-Hydroxybutoxy)-N-(2-(diethylamino)ethyl)-3-pyridinecarboxamide
C16H27N3O3 (309.20523119999996)
Metipranolol
3-(Propan-2-ylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by a 4-acetoxy-2,3,5-trimethylphenoxy group. A non-cardioselective beta-blocker, it is used to lower intra-ocular pressure in the management of open-angle glaucoma. S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics > S01ED - Beta blocking agents C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents Metipranolol is a nonselective and orally active β-adrenergic receptor antagonist. Metipranolol can be used for hypertension and glaucoma research[1][2].
Solgol
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents Nadolol (SQ-11725) is a non-selective and orally active β-adrenergic receptors blocker and is a substrate of organic anion transporting polypeptide 1A2 (OATP1A2). Nadolol has the the potential for high blood pressure, angina pectoris and vascular headaches research[1][2][3].
(2E,5Z,7E)-decatrienoylcarnitine
An O-acylcarnitine having (2E,5Z,7E)-decatrienoyl as the acyl substituent.
(1s,2r,5s,6s,8r,11s)-5-[(dimethylamino)methyl]-2-hydroxy-11-isopropyl-6-methyl-9-oxatricyclo[6.2.1.0²,⁶]undecane-7,10-dione
(13e)-13-ethylidene-18-(hydroxymethyl)-11-methyl-1,11-diazapentacyclo[12.3.1.0²,⁷.0⁸,¹⁷.0¹¹,¹⁶]octadeca-2,4,6,8(17)-tetraen-11-ium
[C20H25N2O]+ (309.19667799999996)
(13s,15s,16z)-16-ethylidene-6-methoxy-1λ⁵,11-diazapentacyclo[13.2.2.0¹,¹³.0⁴,¹².0⁵,¹⁰]nonadeca-4(12),5,7,9-tetraen-1-ylium
[C20H25N2O]+ (309.19667799999996)
8-methyl-6-[(2-methylpropanoyl)oxy]-8-azabicyclo[3.2.1]octan-3-yl (2e)-2-methylbut-2-enoate
(2s)-5-[(2s)-butan-2-yl]-2-ethyl-6-{[(2-hydroxyethyl)amino]methylidene}-4-methoxy-2-methylcyclohex-4-ene-1,3-dione
(1s,2s,3s,7s,8s,8ar)-3-[(1e,3e)-4-cyclopropyl-2-methylbuta-1,3-dien-1-yl]-1-methyl-hexahydro-2h-indolizine-1,2,7,8-tetrol
methyl 1-(2-methyl-3-oxodec-8-enoyl)pyrrolidine-2-carboxylate
methyl (2s)-1-[(2s,8e)-2-methyl-3-oxodec-8-enoyl]pyrrolidine-2-carboxylate
(6s)-6-amino-8-(4-aminocyclohexa-2,5-dien-1-yl)-7-methyl-6-(methylamino)-5-oxooctanoic acid
C16H27N3O3 (309.20523119999996)
(1r,13s,15s,16e)-16-ethylidene-6-methoxy-1λ⁵,11-diazapentacyclo[13.2.2.0¹,¹³.0⁴,¹².0⁵,¹⁰]nonadeca-4(12),5,7,9-tetraen-1-ylium
[C20H25N2O]+ (309.19667799999996)
methyl (2s)-1-[(2s)-2-methyl-3-oxodec-8-enoyl]pyrrolidine-2-carboxylate
(1s,12s,13s,14r,15e,17r)-15-ethylidene-13-(hydroxymethyl)-17-methyl-3,17-diazapentacyclo[12.3.1.0²,¹⁰.0⁴,⁹.0¹²,¹⁷]octadeca-2(10),4,6,8-tetraen-17-ium
[C20H25N2O]+ (309.19667799999996)
(2s,6z)-5-[(2r)-butan-2-yl]-2-ethyl-6-{[(2-hydroxyethyl)amino]methylidene}-4-methoxy-2-methylcyclohex-4-ene-1,3-dione
methyl (2s)-1-[(8e)-2-methyl-3-oxodec-8-enoyl]pyrrolidine-2-carboxylate
2-ethyl-6-{[(2-hydroxyethyl)amino]methylidene}-4-methoxy-2-methyl-5-(sec-butyl)cyclohex-4-ene-1,3-dione
(1s,12s,17r)-15-ethylidene-13-(hydroxymethyl)-17-methyl-3,17-diazapentacyclo[12.3.1.0²,¹⁰.0⁴,⁹.0¹²,¹⁷]octadeca-2(10),4,6,8-tetraen-17-ium
[C20H25N2O]+ (309.19667799999996)
5-[(dimethylamino)methyl]-2-hydroxy-11-isopropyl-6-methyl-9-oxatricyclo[6.2.1.0²,⁶]undecane-7,10-dione
(13e,18r)-13-ethylidene-18-(hydroxymethyl)-11-methyl-1,11-diazapentacyclo[12.3.1.0²,⁷.0⁸,¹⁷.0¹¹,¹⁶]octadeca-2,4,6,8(17)-tetraen-11-ium
[C20H25N2O]+ (309.19667799999996)
4-methoxy-5-methyl-2-[(2e,4e,6e)-octa-2,4,6-trien-2-yl]oxan-3-yl 2-aminoacetate
3-(4-cyclopropyl-2-methylbuta-1,3-dien-1-yl)-1-methyl-hexahydro-2h-indolizine-1,2,7,8-tetrol
(11r,13z,14r,16r,18s)-13-ethylidene-18-(hydroxymethyl)-11-methyl-1,11-diazapentacyclo[12.3.1.0²,⁷.0⁸,¹⁷.0¹¹,¹⁶]octadeca-2,4,6,8(17)-tetraen-11-ium
[C20H25N2O]+ (309.19667799999996)